OTCMKTS:GTHP Guided Therapeutics (GTHP) Stock Price, News & Analysis → Move Your Money Before May 1 (From Stansberry Research) (Ad) Free GTHP Stock Alerts $0.09 -0.01 (-10.28%) (As of 04/26/2024 ET) Add Compare Share Share Today's Range$0.09▼$0.1150-Day Range$0.09▼$0.1652-Week Range$0.06▼$0.30Volume25,099 shsAverage Volume26,061 shsMarket Capitalization$4.87 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartEarningsFinancialsSEC FilingsShort InterestStock AnalysisChartEarningsFinancialsSEC FilingsShort Interest Get Guided Therapeutics alerts: Email Address Ad Weiss RatingsThe Next Step of Their Control Is Here …Earlier this week, Section 702 of the Foreign Intelligence Surveillance Act (FISA) was renewed for an additional two years. What does this mean? It means the government has more time — and more ways — to surveil and control you.4 simple steps to protect your privacy and money before it’s too late. About Guided Therapeutics Stock (OTCMKTS:GTHP)Guided Therapeutics, Inc., a medical technology company, focuses on developing medical devices. It focuses on the commercialization of LuViva, a non-invasive cervical cancer detection device that identifies cervical cancers and precancers painlessly, non-invasively, and at the point-of-care by scanning the cervix with light, then analyzing the light reflected and fluorescent light. The company was formerly known as SpectRx, Inc. and changed its name to Guided Therapeutics, Inc. in February 2008. Guided Therapeutics, Inc. was incorporated in 1992 and is based in Norcross, Georgia.Read More GTHP Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart GTHP Stock News HeadlinesApril 19, 2024 | americanbankingnews.comGuided Therapeutics (OTCMKTS:GTHP) and Positron (OTCMKTS:POSC) Critical ContrastFebruary 20, 2024 | finance.yahoo.comLeading Cervical Cancer Doctors Support Approval of LuViva in China Based on Preliminary Review of Clinical Trial ResultsApril 26, 2024 | Weiss Ratings (Ad)The Next Step of Their Control Is Here …Earlier this week, Section 702 of the Foreign Intelligence Surveillance Act (FISA) was renewed for an additional two years. What does this mean? It means the government has more time — and more ways — to surveil and control you.February 20, 2024 | businesswire.comLeading Cervical Cancer Doctors Support Approval of LuViva in China Based on Preliminary Review of Clinical Trial ResultsNovember 20, 2023 | thestreet.comGuided Therapeutics IncNovember 20, 2023 | finance.yahoo.comGuided Therapeutics Announces Completion of Clinical Study for Chinese Regulatory ApprovalJuly 18, 2023 | seekingalpha.comGTHPFebruary 17, 2023 | abcnews.go.com'It was a trap': Video shows American volunteer likely killed by guided missile in 'deliberate' Russian attackApril 26, 2024 | Weiss Ratings (Ad)The Next Step of Their Control Is Here …Earlier this week, Section 702 of the Foreign Intelligence Surveillance Act (FISA) was renewed for an additional two years. What does this mean? It means the government has more time — and more ways — to surveil and control you.November 9, 2022 | finance.yahoo.comGuided Therapeutics Provides Update of Significant Progress in Chinese Clinical Study for Marketing Approval of the LuViva Advanced Cervical ScanJuly 20, 2022 | finance.yahoo.comGuided Therapeutics Receives Institutional Review Board Approval to Start Clinical Study for FDA Approval of the LuViva® Advanced Cervical ScanJune 9, 2022 | finance.yahoo.comImpel Pharmaceuticals to Present Trudhesa® Data at the 64th Annual Meeting of the American Headache SocietyMay 18, 2022 | stockhouse.comOlive Resource Capital Announces Agreement to Acquire C$2.5M Portfolio of AssetsMarch 31, 2022 | finance.yahoo.comGuided Therapeutics Announces Testing Completion of First 150 Patients in Chinese Clinical Study and Receives Milestone Payment of $177,740November 17, 2021 | finance.yahoo.comGuided Therapeutics Announces Start of Chinese Clinical Trial for Approval to Market and Sell LuViva in ChinaOctober 5, 2021 | finance.yahoo.comGuided Therapeutics Ships LuViva Devices to China for Start of Clinical Trial; Receives Additional $100,000 PaymentSee More Headlines Receive GTHP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Guided Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today4/26/2024Next Earnings (Estimated)5/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Electromedical equipment Sub-IndustryN/A Current SymbolOTCMKTS:GTHP CUSIPN/A CIK924515 Webwww.guidedinc.com Phone(770) 242-8723Fax770-242-8639Employees4Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-3,490,000.00 Net MarginsN/A Pretax Margin-3,560.20% Return on EquityN/A Return on Assets-158.84% Debt Debt-to-Equity RatioN/A Current Ratio0.29 Quick Ratio0.16 Sales & Book Value Annual Sales$100,000.00 Price / Sales55.83 Cash FlowN/A Price / Cash FlowN/A Book Value($0.13) per share Price / Book-0.77Miscellaneous Outstanding Shares55,830,000Free Float18,494,000Market Cap$5.58 million OptionableNot Optionable Beta0.34 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesDr. Mark L. Faupel Ph.D. (Age 69)CEO, President, COO, Acting CFO, Secretary & Director Comp: $156.72kKey CompetitorsMicron SolutionsOTCMKTS:MICRHelius Medical TechnologiesNASDAQ:HSDTENDRA Life SciencesNASDAQ:NDRANuwellisNASDAQ:NUWENon-Invasive Monitoring SystemsOTCMKTS:NIMUView All Competitors GTHP Stock Analysis - Frequently Asked Questions How have GTHP shares performed in 2024? Guided Therapeutics' stock was trading at $0.1535 on January 1st, 2024. Since then, GTHP shares have decreased by 43.1% and is now trading at $0.0873. View the best growth stocks for 2024 here. Are investors shorting Guided Therapeutics? Guided Therapeutics saw a increase in short interest during the month of April. As of April 15th, there was short interest totaling 26,700 shares, an increase of 256.0% from the March 31st total of 7,500 shares. Based on an average daily volume of 28,900 shares, the short-interest ratio is presently 0.9 days. View Guided Therapeutics' Short Interest. When is Guided Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024. View our GTHP earnings forecast. How do I buy shares of Guided Therapeutics? Shares of GTHP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:GTHP) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersThe A.I. story nobody is telling you (Read ASAP)TradeSmithForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingHe Is Giving Away BitcoinCrypto Swap ProfitsFed launches fourth dollar overhaulStansberry ResearchBiden out June 13; Kamala won’t replace him?Paradigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Guided Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
